Vertex Pharma stock holds above 540 USD as Crinetics deal closes and Q2 revenue grows

Vertex Pharma stock remains above the 540 USD mark on the Nasdaq after strong second quarter 2026 figures and the completed acquisition of Crinetics Pharmaceuticals, while analysts see the shares trading modestly above intrinsic value.

Vertex Pharma stock (ISIN US92532F1003) closed at 544.52 USD on the Nasdaq on August 31, 2026, leaving the shares above the 540 USD mark as investors digest strong second quarter 2026 results and guidance for its cystic fibrosis portfolio according to an overview of recent market data as of August 31, 2026. The company is also in focus after announcing on September 1, 2026 that it has completed the acquisition of Crinetics Pharmaceuticals, expanding its endocrinology pipeline per an investor news release.

Q2 2026 results support current valuation

According to a recent earnings summary for the quarter ended June 30, 2026, Vertex Pharma generated revenue of 3.33 billion USD in the second quarter 2026, representing an increase of 12.5 percent compared with the same quarter a year earlier as its cystic fibrosis therapies continued to grow globally. In the same period, earnings per share reached 4.73 USD in Q2 2026, only slightly below a consensus expectation of 4.74 USD, indicating that Vertex largely met analyst forecasts despite the minor shortfall. The same overview notes that analysts on average continue to expect a full year 2026 earnings per share of about 16.86 USD, which investors can use to gauge whether today’s price embeds a demanding or moderate earnings multiple.

Market commentators highlight that at a recent price point of 549.26 USD, a valuation model based on an intrinsic value estimate of 522.44 USD sees the shares trading about 5.1 percent above this internal fair value number, suggesting a modest valuation premium at current levels. At the August 31, 2026 close of 544.52 USD, the company’s market capitalization stood at approximately 138.015 billion USD, underlining Vertex’s position as one of the larger biotechnology names in the S and P 500 index. For DACH-based investors, Vertex Pharma is primarily accessible via its Nasdaq listing, while selected German trading venues offer secondary access to the stock in local trading.

Crinetics acquisition and pipeline outlook

On September 1, 2026 Vertex reported that it had completed the acquisition of Crinetics Pharmaceuticals in a transaction valued at around 10 billion USD, with Crinetics becoming a wholly owned subsidiary. The company emphasized in its investor communication that this deal brings in a late stage endocrinology pipeline, while an associated corporate announcement noted that Jonathan Poole has been named finance chief as part of the post deal leadership structure. A separate analysis of the transaction underlined that Crinetics stock has been delisted from the Nasdaq following completion of the acquisition, signaling that integration is moving ahead.

In addition to its cystic fibrosis franchise, Vertex is building new revenue streams in genetic and endocrine diseases. One sector report dated September 2, 2026 points out that second quarter 2026 sales of the gene editing therapy Casgevy reached 76 million USD, up 78 percent quarter on quarter, with approvals in 39 countries. While that figure is still small compared with the 3.33 billion USD in total revenue for Q2 2026, it illustrates how Vertex is starting to diversify beyond its core franchise, a factor that may support the valuation premium mentioned in recent fair value assessments.

Flagship products and new therapies

Vertex Pharma’s business remains dominated by its cystic fibrosis portfolio, which underpins the 3.33 billion USD revenue recorded in the second quarter 2026 and the 12.5 percent year on year growth for that period. Alongside this established franchise, the company is rolling out the gene editing therapy Casgevy, whose 76 million USD in Q2 2026 sales, up 78 percent quarter on quarter, signal both early commercial traction and the potential for future expansion in sickle cell disease and beta thalassemia indications. For investors, the mix between durable cystic fibrosis cash flows and emerging gene and endocrinology assets is a central element in assessing whether the current price level in the mid 540 USD range is sustainable.

Vertex Pharma stock and current market data

Vertex Pharma stock is listed on the Nasdaq under the ticker VRTX and most recently closed at 547.65 USD as of September 1, 2026 in regular trading, slightly above the August 31, 2026 close of 544.52 USD reported in earlier quote data. Based on the August 31, 2026 close, the company’s market capitalization was about 138.015 billion USD, placing it firmly in the large cap biotechnology segment of the S and P 500. A recent overview also notes that an average analyst target price of 567.04 USD implies upside of around 3.54 percent from the 547.65 USD last close, while a fair value model using a 522.44 USD intrinsic value number suggests that today’s price of 549.26 USD is about 5.1 percent above that fair value benchmark.

Vertex Pharma stock at a glance

• Company: Vertex Pharma Inc.
• ISIN: US92532F1003
• Ticker: VRTX
• Trading venue: Nasdaq
• Price (as of August 31, 2026, 16:00): 544.52 USD
• Market capitalization: 138.015 billion USD (as of August 31, 2026)
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: S and P 500
• Next earnings date: November 2, 2026